

PredOmix launches blood test for early cancer detection in women

23 December 2022 | News

OncoVeryx-F is a patented technology that combines metabolomics and artificial intelligence to detect early cancers

Gurugram-based startup PredOmix has unveiled one-of-its-kind innovative cancer detection blood test, OncoVeryx-F, capable of detecting early-stage cancers in women with a 98% accuracy.

Backed by advanced metabolomics technology coupled with artificial intelligence (AI), the new-age innovation will enable the screening for early-stage cancers. Designed for women, the screening tool accurately diagnoses cancer before tumor development begins.

According to the Lancet study on the disease, India is first in terms of the number of cervical cancer cases after India. The research revealed that out of 40% of the total deaths from cervical cancer, 23% occurred in India. During the last decade, a research effort has been directed toward improving outcomes for ovarian cancer by screening for preclinical, early-stage disease using both imaging techniques and serum markers.

OncoVeryx-F is a patented technology that combines metabolomics and artificial intelligence to detect early cancers. It is a blood-based screening approach that accurately identifies four major female-specific malignancies in a single blood test: breast, endometrium, cervix, and ovary. This is one of the first of its kind Multi Cancer Early Detection (MCED) blood test developed by PredOmix that is now available in India and will aid in determining the presence or absence of cancer as well as the tissue of origin or cancer type.

"Our company has plans to expand its testing capabilities by 2023 for detecting 17 types of cancers in both men and women. As an introductory offer, we are offering the women-specific multi-cancer test at a 50% discount. The test is nominally priced at Rs 12,000", said Dr Kanury V S Rao, Co-Founder & Chief Scientific Officer (CSO), PredOmix.